Form 4: Apellis Pharmaceuticals Acquired by Biogen

Apellis Pharmaceuticals has been acquired by Biogen in a transaction involving $41.00 per share in cash plus a contingent value right.

Summary

• Apellis Pharmaceuticals, Inc. has completed its merger with a subsidiary of Biogen Inc.
• Shareholders receive $41.00 per share in cash plus one non-transferable contingent value right (CVR) per share.
• The CVR entitles holders to potential additional payments of up to $4.00 per share upon the achievement of specific milestones.
• All outstanding stock options and restricted stock units (RSUs) were converted into cash and/or CVRs based on the merger terms.
• Apellis Pharmaceuticals is now a wholly owned subsidiary of Biogen.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive outcome for shareholders, as the acquisition provides a definitive cash exit at a premium, with additional upside potential via CVRs.

Positives

• Shareholders receive a guaranteed cash payment of $41.00 per share.
• Potential for additional upside of up to $4.00 per share through contingent value rights.
• Performance-based RSUs were settled at 200% of target based on relative total shareholder return performance.

Negatives

• Stock options with an exercise price of $45.00 or greater were cancelled without consideration.
• The company ceases to exist as an independent publicly traded entity.

Risks

• The $4.00 per share CVR payment is contingent upon the achievement of specific, undisclosed milestones.
• CVRs are non-transferable, limiting liquidity for holders.

Future Outlook

The company has been acquired and is now a wholly owned subsidiary of Biogen; future operations will be integrated into the parent company.

Industry Context

StockSavvy.ai notes that this acquisition follows a trend of large-cap biopharmaceutical companies acquiring mid-cap firms with specialized assets to bolster their pipelines, particularly in the ophthalmology or rare disease spaces.

Comparison to Industry Standards

• The use of CVRs is a standard mechanism in biopharma M&A to bridge valuation gaps regarding clinical trial outcomes or regulatory approvals.
• The acquisition price reflects a premium typical for strategic biotech buyouts.

Stakeholder Impact

• Shareholders receive cash consideration for their equity.
• Employees and management transition to being part of the Biogen organization.

Next Steps

• Integration of Apellis Pharmaceuticals into Biogen operations.
• Monitoring of milestones related to the CVR agreement for potential future payouts.

Key Dates

Keywords

Apellis Pharmaceuticals, Biogen, Merger, Acquisition, APLS, Contingent Value Right, Tender Offer